PharmaShots | Incisive News in 3 Shots

Subscribe Now

Tris Pharma

Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain

Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain

August 22, 2024

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

May 30, 2024

Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder

Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder

August 17, 2022

Insights+: The US FDA New Drug Approvals in November 2021

Insights+: The US FDA New Drug Approvals in November 2021

December 16, 2021

Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

November 5, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us